Article
Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy.
Thoracic cancer - 1 Jun 2022
Wang Lin, Zhu Yanrong, Zhang Bo, Wang Xi, Mo Hongnan, Jiao Yuchen, Xu Jiachen, Huang Jing
Abstract excerpt
BACKGROUND: Immune checkpoint inhibitors (ICIs) have become standard-of-care in patients with pretreated advanced esophageal squamous cell carcinoma (ESCC). However, reliable biomarkers for clinical outcomes are lacking for ICIs. The exploration of effective biomarkers is therefore needed to optimize patient benefit in the treatment of ESCC. METHODS: Sixty-nine patients with advanced ESCC enrolled at one center...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.